Insider Sale by Director Troy Edward Wilson
On September 14, 2026, Troy Edward Wilson, a Director of Puma Biotechnology, Inc. (NASDAQ:PBYI), executed a sale of 5,000 shares of the company’s common stock under a pre‑arranged 10b5‑1 trading plan that was adopted on June 15, 2026. The transaction generated proceeds of $45,500, with each share sold at $9.10. This price was slightly below the prevailing market price of $9.39 and marginally under the 52‑week high of $9.73. The sale follows a 116% total return for the stock over the preceding year, during which the share price rose from a 52‑week low of $4.30.
Following the disposition, Wilson’s direct holding in Puma Biotechnology decreased to 54,750 shares. In addition, he retains indirect ownership of 400 shares through Child #1 and 150 shares through Child #2, bringing his total indirect stake to 550 shares.
Q2 2026 Financial Performance
Puma Biotechnology reported second‑quarter 2026 results that exceeded market expectations. Revenue for the quarter reached $56.5 million, representing a 9% increase compared with the same quarter in the prior year and surpassing Wall Street’s consensus estimate of $52 million. GAAP earnings were $0.16 per diluted share, well above the anticipated $0.03 per share, marking a return to profitability after a loss in the preceding quarter. The revenue uplift was primarily driven by robust sales of the company’s oncology product, NERLYNX.
Market Reaction and Valuation Commentary
At the time of reporting, Puma Biotechnology’s stock traded up 1.51% (PBYI+1.51%). InvestingPro analysis cited in the article suggests the stock remains undervalued relative to its fair‑value estimate and assigned the company a “GREAT” financial health score of 3.5 out of 5.
---